Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. by Whitworth, Hilary S et al.
LSHTM Research Online
Whitworth, Hilary S; Gallagher, Katherine E; Howard, Natasha; Mounier-Jack, Sandra; Mbwanji,
Gladys; Kreimer, Aimée R; Basu, Partha; Kelly, Helen; Drolet, Mélanie; Brisson, Marc; +1
more... Watson-Jones, Deborah; (2019) Efficacy and immunogenicity of a single dose of human
papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination
regimens: A systematic review of evidence from clinical trials. Vaccine. ISSN 0264-410X DOI:
https://doi.org/10.1016/j.vaccine.2019.12.017
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4655607/
DOI: https://doi.org/10.1016/j.vaccine.2019.12.017
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
Review
Efficacy and immunogenicity of a single dose of human papillomavirus
vaccine compared to no vaccination or standard three and two-dose
vaccination regimens: A systematic review of evidence from clinical
trials
Hilary S. Whitworth a,d,⇑, Katherine E. Gallagher b, Natasha Howard c, Sandra Mounier-Jack c,
Gladys Mbwanji d, Aimée R. Kreimer e, Partha Basu f, Helen Kelly a, Mélanie Drolet g, Marc Brisson g,h,
Deborah Watson-Jones a,d
a Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
b Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom
c Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom
dMwanza Intervention Trials Unit, National Institute of Medical Research, Mwanza, Tanzania
eNational Cancer Institute, National Institute of Health, Bethesda, MD, United States
f International Agency for Research on Cancer, World Health Organization, Lyon, France
gCentre de recherche du CHU de Québec, Université Laval, Quebec, Canada
hDepartment of Social and Preventive Medicine, Laval University, Québec, Canada
a r t i c l e i n f o
Article history:
Received 13 August 2019
Received in revised form 4 December 2019
Accepted 7 December 2019
Available online xxxx
Keywords:
Human papillomavirus
Vaccine
Dosage
Efficacy
Immunogenicity
a b s t r a c t
Objectives: This study aimed to systematically review the literature on the efficacy and immunogenicity
of single-dose HPV vaccination compared to no vaccination or multi-dose schedules among vaccine trial
participants.
Methods: Medline, EMBASE, Global Health Database and Cochrane Central Register of Controlled
Trials were searched for publications and conference abstracts (dated January 1999-August 2018)
using MeSH and non-MeSH terms for human papillomavirus AND vaccines AND (immunogenicity OR
efficacy/effectiveness) AND dosage. Search results were screened against pre-specified eligibility criteria.
Data were extracted from included articles, and a narrative synthesis conducted on efficacy against
HPV16/18 infection and humoral immunogenicity.
Results: Seven of 6,523 unique records identified were included in the review. Six were nested observa-
tional studies of participants randomised to receive two or three doses in three large HPV vaccine trials,
in which some participants did not complete their allocated schedules. One small pilot study prospec-
tively allocated participants to receive one or no vaccine dose. Frequency of HPV16/18 infection was
low (e.g. <1% for 12-month-persistent infection) in all vaccinated participants up to seven years post vac-
cination and did not significantly differ by number of doses (p > 0.05 in all cases). Frequency of infection
was significantly lower in one-dose recipients compared to unvaccinated controls (p < 0.01 for all infec-
tion endpoints in each study). HPV16/18 seropositivity rates were high in all HPV vaccine recipients
(100% in three of four studies reporting this endpoint), though antibody levels were lower with one com-
pared to two or three doses.
Conclusions: This review supports the premise that one HPV vaccine dose may be as effective in prevent-
ing HPV infection as multi-dose schedules in healthy young women. However, it also highlights the pau-
city of available evidence from purpose-designed, prospectively-randomised trials. Results from ongoing
clinical trials assessing the efficacy and immunogenicity of single-dose HPV vaccination compared to
currently-recommended schedules are awaited.
 2019 Published by Elsevier Ltd.
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1. Introduction
In May 2018, the Director General of the World Health Organi-
zation (WHO) issued a global call for action to eliminate cervical
cancer within the 21st century [1]. Cervical cancer is the second
most common cancer among women under 65 years worldwide
(after breast cancer), and the leading cause of cancer-related mor-
tality in women under 70 years in many low and middle-income
countries (LMICs), particularly in sub-Saharan Africa [2]. Nearly
all cases of cervical cancer are caused by infection of the cervix
with human papillomavirus (HPV), a sexually transmitted infection
that can also result in other anogenital cancers, oral cancers, and
clinical sequalae such as anogenital warts (AGW) in men and
women [3]. Achieving the WHO’s goal of cervical cancer elimina-
tion will rely on a number of strategies, including widespread vac-
cination against HPV infection [4].
There are three commercially-available HPV vaccines, Cervarix
(GlaxoSmithKline (GSK) Biologicals, Belgium), Gardasil and
Gardasil-9 (both Merck & Co., United States of America (USA)),
all of which are highly efficacious and immunogenic [5–7]. Whilst
the vaccines were initially licensed in a three-dose schedule, in
2014 the WHO changed its recommendation to a two-dose sched-
ule with an interval of at least six months in immunocompetent
adolescents aged 9–14 years based on evidence of non-inferiority
of post-vaccination antibody levels for two versus three doses (as
well as recognition of cost savings and programmatic advantages
of a two-dose schedule) [8]. A three-dose schedule over six months
is still recommended in persons aged 15 years or older and HIV-
positive individuals. Modelling studies using data from high-
income countries (HICs) suggest that a number of different vacci-
nation strategies (including or excluding cervical screening of older
women) could enable elimination of specific HPV types [9] and cer-
vical cancer [10,11]. However, the current multi-dose schedules
are expensive and complex to deliver, particularly for LMICs [12].
As of November 2019, only 23.5% of low-income and 23.4% of
lower-middle income countries had included HPV vaccination in
their national immunisation schedule, compared with 79.1% of
HICs [13].
Several observational studies have suggested that even a single
dose of HPV vaccine may be effective against vaccine-type HPV
infection [14,15]. A single-dose schedule could significantly reduce
costs of vaccine supply and simplify delivery, thus increasing
accessibility and sustainability of HPV vaccination programmes
in many LMICs [16]. A recent systematic review, aiming to evaluate
vaccine effectiveness against HPV infection and associated clinical
disease by number of doses received through national immunisa-
tion programmes, found some effectiveness afforded by one dose
[17]. Two or three-dose schedules appeared more effective than a
single dose. However, a number of limitations in the studies
included in the review are likely to have impacted on estimates
of effectiveness, most biasing the reduced-dose schedules away
from showing effectiveness. For example, women who did not
complete the recommended dosing schedules were, on average,
of lower socioeconomic status and had earlier reported age of sex-
ual debut, both risk factors for HPV infection at the time of vacci-
nation, potentially resulting in differential rates of undetected
prevalent HPV infection across the dose groups at vaccination.
Additionally, risk of misclassification of both exposure and out-
come were high, the former due to recall bias and the latter due
to diagnostic and/or interviewer bias.
Randomised controlled trials (RCTs) designed to compare the
efficacy and/or immunogenicity of one dose of HPV vaccine versus
two- or three-dose schedules are underway in Costa Rica
(ESCUDDO; NCT03180034), Kenya (KEN-SHE; NCT03675256), the
Gambia (HANDS; NCT03832049) and Tanzania (DoRIS;
NCT02834637]) [15,18]. However, efficacy and immunogenicity
data already exist from participants who received a single dose
of HPV vaccine through earlier clinical trials, typically due to
non-completion of a two- or three-dose schedule [14,15]. Whilst
still considered as observational evidence, these studies benefit
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from inclusion of data on age and HPV infection (viral DNA and
antibody) status at enrolment, as well as reliable reporting of vac-
cination history (i.e. number and timing of doses received), unlike
the studies of national immunisation programmes. We are not
aware of any previous RCTs that specifically randomised partici-
pants to receive a single dose of HPV vaccine. The current study
aimed to systematically review the available literature on the effi-
cacy and immunogenicity of single-dose HPV vaccination com-
pared to either no vaccination or to two- or three-dose schedules
among participants who received HPV vaccine through clinical
trials.
2. Methods
2.1. Study design and research questions
We conducted a systematic review of the literature to address
two key research questions. First, ‘Does one dose of HPV vaccine pro-
vide non-inferior efficacy against HPV infection and associated clinical
outcomes, and produce non-inferior immune responses, compared to a
two-dose or three-dose HPV vaccination schedule?’. Second, ‘Does one
dose of HPV vaccine provide efficacy against HPV infection and associ-
ated clinical outcomes compared to no HPV vaccination?’. We consid-
ered the second research question (to evaluate whether one dose is
better than no dose) important from a public health perspective.
Even if the protection afforded by a single dose is lower than
multi-dose schedules, the impact on population-level infection
prevalence could be high if the reduced costs and simplified deliv-
ery logistics mean that implementation and coverage increase
globally.
Specific objectives were to evaluate whether: (i) rates of
vaccine-type HPV infection and associated clinical disease out-
comes were comparable following one versus two or three doses
of the same HPV vaccine; (ii) rates of vaccine-type HPV infection
and associated clinical disease outcomes were significantly lower
following one dose of HPV vaccine compared to no vaccination;
and (iii) humoral immune responses (antibody seropositivity and
titres) induced by one dose of HPV vaccine were comparable to
those induced by two or three doses of the same vaccine. Our sys-
tematic review was designed to identify and evaluate any previous
clinical trials that specifically randomised participants to receive a
single dose of HPV vaccine (versus other comparator arms), as well
as studies of HPV vaccine clinical trial participants who received
only one dose due to non-completion of an alternative dosing
schedule that they were originally randomised to receive.
2.2. Search strategy
We searched Medline, EMBASE, Global Health Database and
Cochrane Central Register of Controlled Trials systematically for
publications and conference abstracts using Medical subject head-
ing (MeSH) and non-MeSH terms under the following themes:
human papillomavirus AND vaccines AND (immunogenicity OR
efficacy/effectiveness) AND dosage. MeSH terms and operators
were adapted as required for each database searched. The specific
search terms and limits used for each database are provided in
Supplementary Table 1. Searches were limited to articles published
between 01 January 1999 (a highly conservative estimate of the
earliest date at which data on HPV vaccines might be available)
and 14 August 2018, and (where allowed by the database) studies
conducted in humans. No language restrictions were applied. All
database searches were performed by one author (HSW), and
results were exported to a single Endnote library, allowing exclu-
sion of duplicates. HSW additionally hand-searched reference lists
of relevant review articles and all full-text articles identified for
inclusion through the database searches.
2.3. Eligibility screening
Search results were screened using pre-defined eligibility crite-
ria, conforming to the Population/Participants, Intervention,
Comparator, Outcome, Setting/Study design (PICOS) format (Sup-
plementary Table 2) [19]. Titles and abstracts of all search results
were first double-screened for eligibility by two of five reviewers
(HSW, KEG, SMJ, NH, GM), based on a limited number of eligibility
criteria. Articles were excluded if they did not describe a research
study of human participants who had received Cervarix, Gardasil
or Gardasil-9, and/or did not generate data on immunogenicity,
infection and/or disease outcomes. Full texts of all remaining and
potentially-relevant publications were subsequently double-
screened by two of the five reviewers against full eligibility criteria
(Supplementary Table 2). For both abstract and full-text screening,
eligibility results were confirmed by consensus across duplicate
reviews. A third reviewer acted as a tie-breaker where duplicate
screening results were discrepant.
2.4. Data extraction
Data were extracted by one author (HSW) using a standardised
extraction form. Extracted data included: publication details, tar-
get population and setting, study design, study population,
intended and actual intervention and comparators, evaluated out-
comes, results and findings, and authors’ conclusions (Supplemen-
tary Table 3). Tabulated results data were independently extracted
by a second author (HK).
2.5. Quality assessment
Included studies were assessed for selection bias (i.e. the selec-
tion of participants in each dose group), confounding, retention
and survival bias, misclassification of exposure and outcome, and
statistical analysis approach. Study populations were evaluated
for generalisability. Where articles described a sub- or post-hoc
analysis of a clinical trial cohort, the ‘parent’ clinical trial popula-
tion was additionally assessed for generalisability. Biases were
specifically assessed for the probability that they would artificially
increase the vaccine efficacy in the one-dose group, or artificially
decrease the vaccine efficacy in the three-dose group. Quality
assessment findings were compiled in a descriptive synthesis by
one author (KEG), and agreed on by all other authors.
2.6. Data synthesis and analysis
A narrative synthesis was conducted by HSW using three ele-
ments: (i) development of a preliminary synthesis of findings of
included studies; (ii) exploration of relationships within and
between studies; and (iii) assessment of the robustness of the
synthesis.
Infection endpoints evaluated in this review were as reported in
included studies. To standardise statistical reporting of incidence
risk, persistence and prevalence, we used raw event and denomi-
nator data extracted from each article to calculate proportions
(expressed as percentages (%)) and 95% confidence intervals (95%
CI). We used the exact (Clopper-Pearson) method for calculating
CIs for proportions, assuming a binomial distribution. We further
calculated unadjusted infection risk ratios (RRs) and prevalence
ratios (PRs) for one- versus two- or three-dose HPV vaccine arms,
and for one-dose HPV vaccine versus control (no HPV vaccine)
arms. The Haldane-Anscombe correction was used for calculation
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of RRs and PRs where no events were detected in one or both com-
parison arms [20]. Fisher’s exact test (2-sided) was used to assess
for statistical significance between the groups and to compute
p-values. RRs and PRs calculated for one versus two or three doses
must be interpreted with caution because of potential for selection
bias due to differences in follow up between the groups.
In the absence of a known correlate of protection for HPV vac-
cination, we did not limit data capture for this systematic review
to a specified humoral immunogenicity endpoint and instead
included any data on binding and/or neutralising antibody
seropositivity, titres and/or avidity. To standardise statistical
reporting of seropositivity results, we used extracted data on num-
bers of participants seropositive for HPV16/18 antibodies and
denominator data to calculate seropositivity proportions (%) and
95%CIs, as above. Geometric mean (GM) antibody titres or MFI
and 95%CIs are presented as shown in the articles.
Pooling and meta-analysis of data from multiple studies was
not considered appropriate due to heterogeneity in study designs
and methods. All analyses were performed using Stata, version
15.0 (Stata, College Station, Texas).
2.7. Registration
This review was registered in PROSPERO, and the protocol is
available online (registration ID: 110162). Reporting adheres to
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) [19].
3. Results
3.1. Search results
Of 6,523 unique records identified from the four databases
(Fig. 1), 6,026 were excluded during title and abstract screening.
A further 498 articles were excluded during full-text screening.
Nine articles met all eligibility criteria [21–29]. Of these, one [21]
was an erratum to a previously published study [22] (that also
met inclusion criteria) and one [23] summarised data from multi-
ple previously published studies [22,24–26] (all of which also met
inclusion criteria) but did not present any new data or analyses.
Therefore, seven articles were included in this review (Fig. 1;
Table 1) [22,24–29]. No additional eligible records were identified
through screening of reference lists of included articles [22,24–29]
and relevant reviews [5,14,17,21,23,30]. Of the seven included
studies, six were considered as observational studies because allo-
cation to the dosing schedule arms (i.e. one dose versus alternative
schedules or no vaccination) was according to what participants
actually received rather than participants being prospectively allo-
cated to a specific dosing schedule [22,24–28]. One small ran-
domised study prospectively allocated participants to one HPV
vaccine dose versus no vaccination [29].
3.2. Nested observational studies of one-dose HPV vaccination
All six observational studies were based on data from three clin-
ical trials [27,31,32]. Two studies were based on the International
Agency for Research on Cancer (IARC) Trial of Two Versus Three
Doses of HPV Vaccine in India [27,28]. Three studies [22,24,26]
were based on the Costa Rica Vaccine Trial (CVT) [31], and one
[25] was based on combined data from CVT [31] and the Papilloma
Trial Against Cancer in Young Adults (PATRICIA) Trial [32].
3.2.1. IARC India HPV vaccine trial
The IARC India HPV Vaccine Trial was designed as an open-label
cluster-randomised trial aiming to compare two versus three doses
of Gardasil among healthy unmarried females aged 10–18 years
in India [27]. Participants were recruited from 188 geographical
clusters across nine locations from September 2009 and
Records remaining aer screening of 
tles & abstracts: N = 505
Records included in review: N = 7
Records excluded through tle & abstract screening: 
N = 6,026
Records excluded through full text screening: N = 496
Reasons for exclusion
- Not a research study of human subjects who received 2vHPV, 4vHPV or 9vHPV 
through a clinical trial, N = 208
- No post-vaccinaon eﬃcacy or humoral immunogenicity data available, N = 33
- Data not reported for 1 dose vs 0, 2 or 3 doses, N = 255
Records idenﬁed through database searches:
EMBASE, N = 4,292
MEDLINE, N = 4,207
Global Health Database, N = 1,967
Cochrane Central Register of Controlled Trials, N = 552
Records idenﬁed through other sources:
Reference list screening, N = 170
Records remaining aer removal of 
duplicates: N = 6,531
Records remaining aer screening of 
full texts: N = 9
Further exclusions
- 1 erratum to a previously published studya
- 1 arcle summarizing data from previously published studies, with no new data 
or analyses presentedb
Fig. 1. Systematic review flow diagram. aCorrected results presented in the erratum [21] were incorporated into data extraction for the corresponding article [22]. bArticle
[23] presents previously published data from CVT [22,24–26].
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Table 1
Summary of studies selected for inclusion in systematic review, in order of date published.
Reference, location Study design HPV-vaccinated population (healthy females in all studies) Control group
No. in
efficacy
cohort
No. in
immuno.
Cohort
Age at
vaccination
(years)
Baseline HPV16/18 DNA statusa Baseline HPV16/18
Serologya
Vaccine
administered
Vaccination
schedule(s)
Follow-up
duration
Kreimer 2011,
Costa Rica [24]b
Post-hoc analysis of
RCT (CVT)
3,575 NA 18–25 HPV16 and 18 positive excluded;
Unstated proportion HPV16 or 18
positive
Unstated proportion
positive (method not
stated)
Cervarix 3d (M0,1,6), 2d
(M0,1/0,6)
1d (M0)
Efficacy:
4 years
3,578 healthy
females receiving
HAV in CVT
Safaeian 2013,
Costa Rica [22]c
Post-hoc analysis of
RCT (CVT)
NA 390 18–25 5% HPV16 or 18 positive 15% HPV16 positive (by
IgG ELISA)
Cervarix 3d (M0,1,6), 2d
(M0,1/0,6)
1d (M0)
Immuno:
4 years
115 healthy HPV16/
18 seropositive
females in CVT, pre-
vaccination
Kreimer 2015,
multiple LMIC & HIC
worldwide [25]d
Combined
retrospective
analysis of CVT and
PATRICIA data
12,159 NA 15–25 HPV16 and 18 positive excluded;
Unstated proportion HPV16 or 18
positive
Unstated proportion
positive (method not
stated)
Cervarix 3d (M0,1,6), 2d
(M0,1/0,6)
1d (M0)
Efficacy:
4 years
12,194 healthy
females receiving
HAV in CVT or
PATRICIA
Sankaranarayanan
2016, India [27]e
Prospective
observational cohort
study
2,649 1,552 – 1,937 10–18 Not measured; unmarried 5% of immuno. cohort
HPV16 positive, 5%
HPV18 positive; Not
reported for efficacy
cohort (by Luminex)
Gardasil 3d (M0,2,6), 2d
(M0,2/0,6)
1d (M0)
Efficacy:
4 years
Immuno:
3 years
None
Scherer 2016, USA
[29]f
Randomised
unblinded pilot
intervention study.
NA 5 27–45 Not measured HPV16 positive (by IgG
binding assay)
Gardasil 1d (M0) Immuno:
6 months
5 healthy HPV16-
seropositive
unvaccinated
females
Sankaranarayanan
2018, India [28]e
Prospective
observational cohort
study
5,655 879 – 1937 10–18 Not measured; unmarried Not reported Gardasil 3d (M0,2,6), 2d
(M0,2/0,6)
1d (M0)
Efficacy:
7 years
Immuno:
4 years
1,481 age-matched
healthy
unvaccinated
females
Safaeian 2018, Costa
Rica [26]g
Prospective
observational cohort
study of prior CVT
participants
2,449 486 18–25 8% HPV16/18 positive 38% HPV16/18 positive
(by IgG ELISA)
Cervarix 3d (M0,1,6), 2d
(M0,1/0,6)
1d (M0)
Efficacy &
immuno:
7 years
2,386 age-matched
healthy
unvaccinated
females
CVT: Costa Rica Vaccine Trial; D: Dose; HAV: Hepatitis A vaccine; HIC: High income county; HPV: Human papillomavirus; Immuno.: Immunogenicity; LMIC: Low or middle-income country; M: Month; No.: Number; PATRICIA:
Papilloma Trial Against Cancer in Young Adults Trial; USA: United States of America.
a HPV16/18 DNA status refers to PCR/genotyping results in cervical samples; HPV16/18 serology refers to antibody seropositivity results in serum or plasma. Baseline refers to pre-vaccination.
b Analytic cohort included all 7,153 CVT participants who were seen each year during four years of follow-up, and who were not HPV16 and 18 DNA positive at baseline. At enrolment, participants were randomised to receive
HPV vaccine (n = 3,575) or HAV (3,578). HAV control arms received vaccine and were followed up according to the same schedule as HPV vaccine arms.
c Included all 270 CVT participants who received one or two HPV vaccine doses, and a random selection of 120 participants who received three HPV vaccine doses, all with sera available for each study visit. Pre-vaccination
samples from 115 HPV16/18-seropositive CVT participants (DNA status not reported) were used as single timepoint controls.
d Analytic cohort included all 25,055 CVT and PATRICIA participants who had adequate follow up and available HPV DNA results at baseline, and who were not HPV16 and 18 DNA positive at baseline. Inadequate follow up was
defined as no M12 or later visit, or <300 days between the M12 (or later) visit and the last study visit. At enrolment, participants were randomised to receive HPV vaccine (n = 21.013) or HAV (12,042). HAV control arms received
vaccine and were followed up according to the same schedule as HPV vaccine arms. Results were additionally reported in the study for a ‘naïve’ cohort excluding women who were HPV DNA positive for any of 14 high-risk HPV
types, HPV16/18 seropositive, and cytology positive at enrolment. Results from the ‘naïve’ cohort are not included in the current systematic review.
e Efficacy cohort included all IARC India HPV Vaccine Trial participants (all unmarried at enrolment) who received one or more doses of HPV vaccine and had at least one cervical sample collected during follow up (2,649 up to
Y4; 5,655 up to Y7). Collection of cervical samples commenced six months after delivery of a baby or 12 months after marriage, whichever was earlier. Participants for the immunogenicity cohort were selected by convenience
sampling; numbers of samples vary at each time point. 1,481 age-matched healthy married and HPV-unvaccinated control participants were enrolled two years after the start of enrolment into the IARC India HPV Vaccine Trial and
followed up for four years.
f Included 10 HPV16-positive females with  5 heterosexual lifetime partners. Five were randomised to receive one dose of Gardasil and five to receive no vaccine. Both arms were enrolled together and followed up at the same
timepoints.
g Efficacy cohort included all 2,449 HPV-vaccinated CVT participants who agreed to enter the long-term follow up study at the end of the four-year trial. The immunogenicity cohort included a subset of 321 one- or two-dose
participants who were tested previously [22] and had sufficient available sera, and a random subset of 165 three-dose participants. 2,836 age-matched healthy and HPV-unvaccinated women were enrolled at the start of the long-
term follow up study and followed up for three years.
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randomised to either two or three dose arms by computer-
generated random allocation. However, in April 2010, the Indian
government suspended all HPV vaccine trials for reasons not
related to the IARC India HPV Vaccine Trial, and enrolment into
the trial therefore stopped early. At the point of suspension,
17,729 participants had been recruited (88.6% of the targeted
recruitment of 20,000 girls), but many had not yet completed their
full dose schedules. Thus, the clinical trial of two versus three HPV
vaccine doses became a prospective observational cohort study of
one versus two versus three vaccine doses.
Of the two publications arising from the IARC India HPV Vaccine
Trial, the first presents HPV infection and immunogenicity data up
to 48 months following the first vaccine dose for participants who
received one dose (at day (d) 0), two doses (at d0 and either month
(m) 2 or m6) and three doses (at d0, m2 and m6) [27]. The second
presents immunogenicity data up to 48 months, and HPV infection
data up to seven years, following the first vaccine dose for the same
dosing schedules [28]. A supplementary cohort of married, unvac-
cinated females aged 18–23 years (corresponding to the age of the
married vaccinated females at the time of follow up) was recruited
from different study sites in India during 2012 to 2015, allowing
comparison of HPV infection data between participants vaccinated
with one, two or three doses and those who had not received any
vaccine doses.
3.2.2. CVT
The CVT was a community-based double-blind RCT aimed at
evaluating the efficacy of a three-dose regimen of Cervarix against
persistent vaccine type-specific HPV infection and subsequent
development of HPV-associated pre-cancerous lesions among
healthy women aged 18–25 years in two regions of Costa Rica
[31]. Potential participants were identified from a census of young
females conducted in the target regions four years earlier. A total of
7,466 women were recruited from seven study clinics between
June 2004 and December 2005, all of whom were randomized to
receive three doses of either HPV vaccine or Hepatitis A vaccine
(HAV; control). Some women did not complete their full vaccina-
tion schedule for reasons including pregnancy, colposcopy referral,
other medical conditions, vaccine refusal or missed study visits.
The first identified one-dose study arising from CVT describes a
post-hoc analysis of HPV infection data up to 48 months following
first vaccine dose in participants who received one dose (at d0),
two doses (at d0 and either m1 or m6) and three doses (at d0,
m1 and m6) [24]. The second study describes a post-hoc analysis
of HPV vaccine-induced immunogenicity up to m48 for the same
dosing schedules [22]. A subsequent manuscript extends these
HPV infection and immunogenicity data from this study to seven
years following first vaccine dose [26]. At the completion of the
randomized, blinded phase of CVT, control participants were
offered the HPV vaccine. Thus, for the most recent (2018) study,
a new cohort of 2,836 unvaccinated women, age-matched to the
trial participants, were recruited to replace the original control
group [26].
3.2.3. PATRICIA trial
The PATRICIA trial was a large-scale phase III double-blind RCT
among healthy women aged 15–25 years from 14 countries in Asia
Pacific, Europe, Latin America and North America, also aiming to
evaluate the efficacy of a three-dose regimen of Cervarix [32].
The PATRICIA trial enrolled 18,729 women between May 2004
and June 2005, all of whom were randomised to receive three
doses of HPV or HAV (control). 18,644 women received at least
one vaccine dose; some participants did not receive all scheduled
doses for similar reasons as in CVT.
One study identified for inclusion in our systematic review
reports a post-hoc analysis of combined CVT and PATRICIA trial
data [25]. This publication describes HPV infection data up to
48 months following first vaccine dose in participants who
received one dose (at d0), two doses (at d0 and either m1 or m6)
and three doses (at d0, m1 and m6).
3.3. Intervention study of one-dose HPV vaccination
The only intervention study is a small pilot study conducted in
the USA aimed at evaluating memory B cell responses following
one dose of HPV vaccine compared to no vaccine in participants
with prior HPV16 infection [29]. The study randomised ten healthy
HPV16-seropositve women aged 27–45 years at d0 to receive one
dose of Gardasil or no intervention. Humoral immunogenicity
results for the two arms are presented up to m6. Additional mem-
ory B cell evaluations described in the paper were outside the
remit of this review.
3.4. HPV16 and 18 infection
HPV16 and 18 infection results for participants who received
one HPV vaccine dose compared to any comparator group are
reported in five of the included studies [24–28]. HPV infection-
related outcome measures most commonly reported include one-
time or cumulative incident infection, and 6 or 12-month persis-
tent infection. Three studies report results up to four years post-
vaccination [2], and two up to seven years. Methods used for detec-
tion of infection and definitions of endpoints reported by each of
the five studies are summarised in Supplementary Table 4.
Table 2 summarises efficacy results for each of the five studies.
Incident, persistent and prevalent infection with HPV16 and 18
were extremely low in all participants who received any HPV vac-
cine, and significantly lower than participants who were either
unvaccinated or received HAV. All studies reported comparable
efficacy against HPV16 and 18 infection in one-dose and two- or
three-dose arms. In CVT, vaccine efficacy against incident
12-month persistent HPV16 or 18 infection at four years post vac-
cination with 2vHPV (when participants were aged 22–29 years)
was 80.9% (95%CI 71.1–87.7%) in the three-dose arm, 84.1% (95%
CI 50.2–96.3%) in the two-dose arm, and 100% (95%CI 66.5–100%)
in the one-dose arm. In the PATRICIA trial, equivalent vaccine effi-
cacies (when participants were aged 19–29 years) were 88.2% (95%
CI 84.6% to 91.0%), 100% (95% CI 60.7–100%) and 76.8% (95% CI
118 to 99.1%), respectively. In the IARC India HPV vaccine trial,
no persistent HPV 16 or 18 infections were detected in any of the
dosage groups (one, two or three doses) at four years post vaccina-
tion with 4vHPV (when participants were 14–22 years).
At seven years post vaccination in CVT (when participants were
aged 25–32 years), cumulative incident HPV16/18 infection among
2vHPV recipients ranged from 1.5% (95%CI 0.2–5.3%) in the one-
dose arm to 4.3% (95%CI 3.5–5.3%) in the three-dose arm. In the
IARC India HPV vaccine trial, cumulative incident HPV16 and 18
infections at the same time point (when participants were aged
17–25 years) was 0.9% (95%CI 0.5–1.7%) in the three-dose arm,
0.9% (95%CI 0.5–1.7%) in the two dose arm, and 1.6% (95%CI 1.1–
2.3%) in the one-dose arm. The rates of persistent HPV16 or
HPV18 infection in the IARC trial at 7 years were 0.2% (95%CI
0.0–0.9%) in the three-dose arm, 0% each in two-dose and single-
dose arms and 1.2% (95% CI 0.7–2.1%) in the unvaccinated women.
None of the included studies reported efficacy against other
HPV-associated endpoints, such as pre-cancerous lesions or
anogenital warts.
3.5. Immunogenicity results
HPV16 and 18 humoral immunogenicity results for participants
who received one HPV vaccine dose compared to any comparator
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Table 2
Summarised HPV16/18 infection results up to four and seven years following vaccination from studies reporting efficacy data for participants who received one versus two or three vaccine doses, and versus unvaccinated participants.
Reference Follow up
duration
Infection
endpointa
3 dose HPV arm 2 dose HPV armb 1 dose HPV arm Control armc RR or PR (95%CI), p valued
# events /
participants
%
(95%CI)d
# events /
participants
%
(95%CI)d
# events /
participants
%
(95%CI)e
# events /
participants
% (95%CI)d 1 dose/
3 dosese
1 dose/
2 dosese
1 dose/
control
CERVARIX
One-time incident and cumulative incident infections
Kreimer 2015[25] Mean: 4.0y
SD: 0.7y
One-time
incident
529/11,110 4.8
(4.4–5.2)
22/611 3.6 (2.3–5.4) 8/292 2.7 (1.2–5.3) 45/251 17.9
(13.4–23.2)
0.6 (0.3–1.1)
0.12
0.8 (0.3–1.7)
0.56
0.2 (0.1–0.3)
< 0.01
Safaeian 2018[26] Median:
6.9y
IQR:
6.5–7.3y
One-time
incident
9/2,042 0.4
(0.2–0.8)
0/78 0.0 (0.0–4.6) 0/134 0.0 (0.0–2.7) – – 0.8
(0.0–13.6)
1.0
0.6
(0.0–29.2)
UTCi
–
Cumulative
incident
88/2,036 4.3
(3.5–5.3)
3/78 3.8
(0.8–10.8)
2/133 1.5 (0.2–5.3) – – 0.3 (0.1–1.4)
0.17
0.4 (0.1–2.3)
0.36
–
One-time prevalent infections
Safaeian 2018[26] Median:
6.9y
IQR:
6.5–7.3y
One-time
prevalent
20/2,043 1.0
(0.6–1.5)
1/79 1.3 (0.0–6.9) 0/134 0.0 (0.0–2.7) 158/2,382 6.6 (5.7–7.7) 0.4 (0.0–6.1)
0.63
0.2 (0.0–4.8)
0.37
0.1 (0.0–0.9)
<0.01
Persistent infectionsh
Kreimer 2011[24] Median:
4.2yg
6 m
persistent
37/2957 1.3
(0.9–1.7)
5/422 1.2 (0.4–2.7) 0/196 0.0 (0.0–1.9) 15/188 8.0 (4.5–12.8) 0.2 (0.0–3.2)
0.17
0.2 (0.0–3.5)
0.18
0.0 (0.0–0.5)
<0.01
12 m
persistent
25/2957 0.9
(0.6–1.2)
3/422 0.7 (0.1–2.1) 0/196 0 0.0 (0.0–
1.9)
10/188 5.3 (2.6–9.6) 0.3 (0.0–4.8)
0.40
0.3 (0.0–5.9)
0.56
0.0 (0.0–0.8)
<0.01
Kreimer 2015[25] Mean: 4.0y
SD: 0.7y
6 m
persistent
114/11,104 1.0
(0.8–1.2)
4/611 0.7 (0.2–1.7) 1/292 0.3 (0.0–1.9) 24/250 9.6 (6.2–13.9) 0.3 (0.0–2.4)
0.37
0.5 (0.1–4.7)
1.00
0.0 (0.0–0.3)
<0.01
12 persistent 84/11,104 0.8
(0.6–0.9)
3/611 0.5 (0.1–1.4) 1/292 0.3 (0.0–1.9) 17/249 6.8 (4.0–10.7) 0.5 (0.1–3.2)
0.72
0.7 (0.1–6.7)
1.00
0.1 (0.0–0.4)
<0.01
GARDASIL
One-time incident and cumulative incident infections
Sankaranarayanan 2016
[27]
Median:
4.7y
IQR:
4.2–5.1y
Cumulative
first incident
2/536 0.4
(0.0–1.3)
4/526 0.8 (0.2–1.9) 10/870 1.1 (0.6–2.1) – – 3.1
(0.7–14.0)
0.17
1.5 (0.5–4.8)
0.059
–
Sankaranarayanan 2018
[28]
Up to 7yf Cumulative
incident
11/1,180 0.9
(0.5–1.7)
11/1,179 0.9 (0.5–1.7) 30/1,823 1.6 (1.1–2.3) 92/1,481 6.2 (5.0–7.6) 1.8 (0.9–3.5)
0.1
1.8 (0.9–3.5)
0.1
0.3 (0.2–0.4)
<0.01
Persistent infectionsh
Sankaranarayanan 2018
[28]
Up to 7yf 12 m
persistent
1/604 0.2
(0.0–0.9)
0/608 0.0 (0.0–0.6) 0/959 0.0 (0.0–0.4) 14/1,141 1.2 (0.7–2.1) 0.2 (0.0–5.1)
0.39
0.6
(0.0–31.9)
UTCi
0.0 (0.0–0.7)
<0.01
CI: confidence interval; HPV: Human papillomavirus; IQR: Inter-quartile range; M; Month; PR: Prevalence ratio; RR: Risk ratio; SD: Standard deviation; UTC: Unable to compute; Y: Year.
a Definitions of infection endpoints used in each study are provided in Supplementary Table 4.
b Results are shown only for two-dose arms where participants received dose one at day 0 and dose two at day 180.
c Results are shown for one-dose control vaccine (HAV) arms for Kreimer et al. [24] and Kreimer et al. [25], and unvaccinated control arms for Sankaranarayanan et al. [28] and Safaeian et al. (2018; persistent infection only) [26].
Comparison of the single-dose HPV vaccine arm with the single-dose HAV (rather than multi-dose HAV) arm in the Costa Rica trial minimises the potential for selection bias due to differences in follow up. No control arm was
reported in Sankaranarayanan et al. [27].
d Proportions (%), unadjusted RRs and PRs, 95%CIs and 2-sided Fisher’s exact p values were calculated by the authors of this review using data provided in the included articles. Haldane-Anscombe correction was used for
calculation of RRs and PRs where no events were detected in one or both comparison arms [20]. In most cases, the 95%CIs for proportions calculated by the authors of this review matched those reported in the included studies.
Where they do differ, the 95%CIs calculated in this review are wider than those reported in the articles.
e Risk and prevalence ratios calculated for one versus two or three doses must be interpreted with caution because of potential for selection bias due to differences in follow up between the groups.
f Mean, median, IQR or SD were not reported for this study.
g IQR or SD were not reported for this study.
h Sankaranarayanan et al. detected no persistent infections in any arm up to the median follow up of 4.7y among 838 women with two or more samples available for analysis [27].
i STATA does not compute a p value using Fisher’s exact test where both numerators are 0.
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group are reported in five of the included studies [22,26–29].
HPV16 and 18 immunogenicity-related outcome measures most
commonly reported include: seropositivity, geometric mean (GM)
antibody levels (titres or MFI) and antibody stability. Some studies
additionally reported on antibody avidity (the strength at which an
antibody binds to an antigen) or seropositivity and/or titres of neu-
tralising antibodies (antibodies that specifically prevent viral infec-
tion of a cell though neutralisation of its biological effect). Methods
used for measurement of immune responses and, where applica-
ble, definitions of endpoints reported by each of the five studies
are summarised in Supplementary Table 5.
Table 3 summarises seropositivity, antibody level and stability
results for the four studies comparing one dose versus other vac-
cine dosage schedules. The proportions of participants reportedly
seroconverting to HPV16 and/or 18 antibody-positive were gener-
ally high in all HPV vaccine arms, reaching 100% in some studies.
However, the definition of seroconversion differs between studies
(Supplementary Table 5). Antibody levels were significantly lower
with one dose than for two or three doses However, whilst levels
for two and three-dose arms declined following an initial increase,
plateauing thereafter, this trend was typically less pronounced in
the one-dose arms, in which levels remained more stable through-
out follow-up (Fig. 2). Furthermore, antibody levels were signifi-
cantly higher in participants vaccinated with one dose of HPV
vaccine compared to pre-vaccination levels in participants with
natural infection (where included).
In CVT, post-vaccination HPV16/18 antibody avidity was lower
in the reduced dosage groups; however, avidity remained stable
between the 4 and 7-year time points within each of the dosage
groups. Proportions of CVT participants who were seropositive
for HPV16/18 neutralising antibodies at month 48 were similar
across the HPV vaccine dosage arms. In the IARC India HPV vaccine
trial, HPV16/18 antibody avidity was comparable across the dosage
groups at 18 months post vaccination, but neutralising antibody
levels were lower in reduced dose schedules.
In the small randomised study by Scherer et al., four of the five
HPV16-seropositive women receiving one dose of HPV vaccine
exhibited increases in HPV16 and 18 binding antibody levels and
neutralisation against HPV16 by one month following vaccination,
and responses remained increased compared to baseline at month
6. Two women had increases in HPV16 and 18 binding antibody
levels at one week post vaccination. Conversely, non-neutralising
antibodies were observed in women with natural HPV infection,
and no changes in antibody responses were seen among the five
infected women who did not receive any HPV vaccine dose.
3.6. Quality assessment
The quality of evidence from all seven studies was assessed, and
a descriptive synthesis is presented in Supplementary Table 6 for
the CVT, PATRICIA and IARC India HPV Vaccine trials. The presence
of enrolled comparator groups of young women who did not
receive HPV vaccine in these trials allowed authors to assess the
risk of bias and the presence of a number of confounders that could
have artificially inflated the vaccine efficacy in the one-dose group
or deflated the vaccine efficacy in the three-dose group. Sociode-
mographic characteristics (e.g. age, household income, education
level), HPV seropositivity at baseline, and the incidence of non-
vaccine type HPV infections during follow up (proxy measures
for participants’ risk of HPV16/18 exposure during follow-up) were
very similar across comparator groups (dose groups and control
groups). Participants’ reasons for non-completion of the vaccina-
tion schedule and rates of loss-to-follow up (indicators of survival
bias) were also very similar across all comparator groups and were
controlled for in some analyses conducted by the authors of the
included studies (but not analyses conducted in this systematic
review). The risk of exposure or outcome misclassification was
low and the included analyses were appropriate.
The intervention study by Scherer et al. was a very small (n = 5
per arm) pilot study among HPV16 seropositive women, limiting
the precision of estimates and generalizability of results. Allocation
to one-dose HPV vaccine versus no intervention was randomized
but not blinded; however, the latter point likely has little implica-
tion as the study endpoints were immunological.
4. Discussion
Our systematic review presents strong epidemiological evi-
dence that a single dose of HPV vaccine may be protective against
HPV16 and HPV18 infection. The five included studies that evalu-
ated efficacy endpoints found that HPV16/18 infection was rare
(0% to <5% for one-time incident infection, and 0% to <1% for 12-
month persistent infection) among participants who received any
HPV vaccination up to four or seven years after dose one, regard-
less of the number of doses received [24–28]. Infection rates were
significantly lower in all HPV vaccine arms than in study partici-
pants who were either unvaccinated or received control vaccine.
Furthermore, no study found any difference in HPV16/18 infection
incidence, persistence or prevalence between participants who
received one versus two versus three HPV vaccine doses by year
four or year seven.
Our findings contrast with the conclusions of a previous sys-
tematic review of data from national HPV vaccination pro-
grammes, which included two studies evaluating efficacy of
Cervarix against HPV16/18 prevalence at 4–5 years post vaccina-
tion [17]. One study reported statistically significant effectiveness
for one, two and three doses of HPV vaccine compared to no vacci-
nation, but effectiveness was lower for one-dose than for multi-
dose schedules [33]. The other study found statistically significant
effectiveness for three, but not one or two, vaccine doses compared
to no vaccination [34]. Other studies included in the same review
reported either no efficacy of single-dose HPV vaccination, or
reduced efficacy compared to two- or three-dose schedules, for
other clinical endpoints including anogenital warts and cervical
abnormalities [17]. However, as reported by the review authors,
several features of the included studies could have led to an under-
estimation of the effectiveness of one or two-dose schedules. In
particular, recipients of one- or two-doses in national programmes
where three-dose schedules were recommended proved to be, on
average, older at vaccination, of lower socioeconomic status, and
younger at first sexual exposure. These factors may be associated
with higher risk of HPV infection at vaccination and exposure
post-vaccination, both of which would adversely impact vaccine
effectiveness estimates of one or two doses.
CVT and PATRICIA trial participants were tested for HPV infec-
tion prior to vaccination, enabling the subsequent analyses
included in those studies and our review to evaluate effectiveness
of HPV vaccine by number of doses received specifically among
participants who were HPV16/18 DNA negative at baseline.
Although the IARC India HPV Vaccine Trial did not test for HPV
infection at baseline, participants were young unmarried females
who were likely to have a very low risk of HPV infection at base-
line. Additionally, regular sampling throughout the follow-up per-
iod in CVT, PATRICIA and the IARC India HPV Vaccine Trial allowed
detection of new infections occurring post-vaccination. In the indi-
vidual study analyses, vaccine efficacies for each HPV vaccine dose
group were calculated against control groups who did not receive
HPV. Control groups and their respective HPV vaccine dose groups
were balanced with respect to potential confounders, such as prox-
ies of sexual activity and economic status.
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Table 3
Summarised HPV16/18 seroprevalence, GM antibody level and antibody avidity results up to 84 months following vaccination from studies reporting immunogenicity data for participants who received one versus two or three doses.
Reference Time point # seropositiveb/participants (% Seropositive, 95%CIc) GM titers/MFI (95%CI)
3 doses 2 dosesa 1 dose 3 doses 2 dosesa 1 dose Naturally-
infected
CERVARIX
HPV16
Safaeian 2013 [22]d D0 18/120 (15.0, 9.1–22.7) – 6/78 (7.7) <LOD <LOD <LOD –
M6 – – – 724 EU/ml 102 EU/ml 145 EU/ml –
M12 – – – 2,034 EU/ml 1,484 EU/ml 115 EU/ml –
M24 – – – 1,115 EU/ml 837 EU/ml 124 EU/ml –
M36 – – – 899 EU/ml 642 EU/ml 136 EU/ml –
M48 78/79 (98.7, 93.1–100.0) 52/52 (100.0, 93.2–100.0) 120/120 (100, 97.0–100.0) 748 EU/ml (648–865) 520 EU/ml (422–641) 137 EU/ml
(106–178)
15 EU/ml (11–19)
Safaeian 2018 [26] M48 2,043/2,043 (100.0,
99.8–100.0)
79/79 (100.0, 95.4–100.0) 134/134 (100.0,
97.3–100.0)
803 EU/ml (708–909) 555 EU/ml (447–690) 205 EU/ml
(165–255)
–
M84 2,043/2,043 (100.0,
99.8–100.0)
79/79 (100.0, 95.4–100.0) 134/134 (100.0,
97.3–100.0)
716 EU/ml (630–814) 460 EU/ml (367–576) 194 EU/ml
(158–237)
–
HPV18
Safaeian 2013 [22]d D0 – – – <LOD <LOD <LOD –
M6 – – – 408 EU/ml 53 EU/ml 76 EU/ml –
M12 – – – 827 EU/ml 763 EU/ml 71 EU/ml –
M24 – – – 471 EU/ml 446 EU/ml 69 EU/ml –
M36 – – – 369 EU/ml 358 EU/ml 74 EU/ml –
M48 – – – 335 EU/ml (285–392) 305 EU/ml (238–391) 70 EU/ml (54–91) 15 EU/ml (12–19)
Safaeian 2018 [26] M48 2,043/2,043 (100.0,
99.8–100.0)
79/79 (100.0, 95.4–100.0) 134/134 (100.0,
97.3–100.0)
360 EU/ml (313–414) 296 EU/ml (240–366) 112 EU/ml (93–134) –
M84 2,043/2,043 (100.0,
99.8–100.0)
79/79 (100.0, 95.4–100.0) 134/134 (100.0,
97.3–100.0)
322 EU/ml (281–369) 270 EU/ml (221–330) 125 EU/ml (105–150) –
GARDASIL
HPV16
Sankaranarayanan
2016 [27]e
D0 46/1,000 (4.6, 3.4–6.1) 52/937 (5.5, 4.2–7.2) – MFI 11 (10–12) MFI 9 (8–10) – –
M7 308/308 (100.0, 98.8–100.0) 316/317 (99.7, 98.3–100.0) – MFI 5,460
(5,195–5.738)
MFI 6,125
(5,785–6,485)
– –
M12 – – 260/528 (49.2, 44.9–53.6) – – MFI 106 (96–116) –
M18 311/313 (99.4, 97.7–99.9) 312/314 (99.4, 97.7–99.9) 255/476 (53.6, 49.0 – 58.1) MFI 1,209
(1,105–1,323)
MFI 1,222
(1,116–1,338)
MFI 113 (102–126) –
M36 225/271 (83.0, 78.0–87.3) 197/278 (70.9, 65.1–76.1) 166/510 (32.5, 28.5–36.8) MFI 221 (197–247) MFI 163 (147–181) MFI 72 (66–78) –
Sankaranarayanan
2018 [28]
M36 271/271 (100.0, 98.6–100.0) 278/278 (100.0, 98.7–
100.0)
510/510 (100.0,
99.3–100.0)
MFI 221 (197–247) MFI 163 (147–181) MFI 72 (66–78) –
M48 239/239 (100.0, 98.5–100.0) 243/243 (100.0, 98.5–
100.0)
397/397 (100.0,
99.1–100.0)
MFI 196 (170–226) MFI 197 (172–225) MFI 86 (75–99) –
HPV18
Sankaranarayanan
2016 [27]e
D0 41/1,000 (4.1, 3.0–5.5) 63/937 (6.7, 5.2–8.5) – MFI 6 (5–7) MFI 5 (4–5) – –
M7 308/308 (100.0, 98.8–100.0) 317/317 (100.0, 98.8–
100.0)
– MFI 2,942
(2,733–3,167)
MFI 3,068
(2,812–3,347)
– –
M12 – – 304/528 (57.6, 53.2–61.8) – – MFI 50 (45–55) –
M18 307/313 (98.1, 85.9–99.3) 305/314 (97.1, 94.6–98.7) 259/476 (54.4, 49.8–59.0) MFI 377 (337–422) MFI 269 (241–299) MFI 46 (40–51) –
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Direct comparisons of vaccine efficacy across different HPV vac-
cine dose groups (for example, one versus two doses, and one
verses three doses, as presented in this review) could be affected
by selection bias by comparing potentially different populations.
The risk is that the one-dose groups are, on average, less healthy
and more at risk of HPV infection than the three-dose groups.
Despite this potential bias, vaccine efficacy is high in the one-
dose group, and point estimates are comparable across the dose
groups (albeit with wide confidence intervals). Furthermore, in
the CVT, PATRICIA and IARC India HPV Vaccine trials the incidence
of infection with HPV genotypes not targeted by the allocated HPV
vaccines was similar across vaccinated participants, regardless of
the number of doses received, providing further reassurance
against potential bias and confounding relating to underlying char-
acteristics of participants not completing their allocated vaccine
schedule.
From the five included studies reporting immunogenicity end-
points, most (and, in some studies, all) participants who were
HPV16/18 seronegative at baseline and vaccinated against HPV
seroconverted to HPV16 and/or 18, regardless of the number of
doses received [22,26–28]. HPV16/18-specific antibody levels were
significantly higher post-vaccination in participants who received
multiple vaccine doses compared to those who received only one
dose. However, levels were significantly higher in one-dose partic-
ipants than in unvaccinated controls with natural infection. A
recent systematic review found that HPV antibodies acquired
through natural HPV infection were protective against later HPV
infection in females [35]. Thus, the observed antibody levels
induced by single-dose HPV vaccination are likely to be clinically
beneficial. Also, whilst levels among two- or three-dose partici-
pants typically increased up to approximately 12 months after vac-
cination and then declined significantly before plateauing, levels in
one-dose participants remained relatively stable after the initial
increase (up to the end of follow up in each study). In the few stud-
ies evaluating neutralising antibodies, seroconversion rates were
very high across all HPV vaccine arms but, again, absolute levels
were significantly higher in those receiving multiples doses.
Two key studies have compared immune responses following
one- versus multi-dose HPV vaccination provided through national
immunisation programmes [36,37]. Similarly to the study results
included in our review, LaMontagne et al. found higher HPV16/18
GM titres approximately 40 months following vaccination in
two- and three-dose compared to one-dose Cervarix recipients
(aged 10–11 years at the time of vaccination; all female) in Uganda
[36]. Toh et al. detected lower HPV16/18-specific neutralising anti-
body titres among Fijian girls aged 15–19 years who received one
compared to two or three doses of Gardasil six years previously,
though titres were five to 30 times higher in one-dose participants
than in unvaccinated controls [37]. However, in both studies, the
percentage of girls who were seropositive for vaccine-type HPV
antibodies was high across all vaccinated arms, regardless of the
number of doses received. In a subsequent Canadian study of girls
aged 13–18 years, all were HPV16/18 seropositive following a sin-
gle dose of Gardasil provided through the national vaccination
program three to eight years previously [38]. These immunogenic-
ity studies are informative but affected by many of the same limi-
tations as the national programme-based efficacy studies included
in the previous systematic review by Markowitz et al. [17].
Although the evidence suggests that magnitudes of antibody
responses are lower following single-dose HPV vaccination com-
pared to multi-dose schedules, this may have limited clinical sig-
nificance. All three studies in our systematic review evaluating
infection and immunogenicity endpoints within the same popula-
tions reported comparable efficacy of one-, two- and three doses of
HPV vaccination against HPV16/18 infection despite differences in
antibody levels between the groups [26–28]. The lower limit ofTa
bl
e
3
(c
on
ti
nu
ed
)
R
ef
er
en
ce
Ti
m
e
p
o
in
t
#
se
ro
p
o
si
ti
ve
b
/p
ar
ti
ci
p
an
ts
(%
Se
ro
p
o
si
ti
ve
,9
5%
C
Ic
)
G
M
ti
te
rs
/M
FI
(9
5%
C
I)
3
d
o
se
s
2
d
o
se
sa
1
d
o
se
3
d
o
se
s
2
d
o
se
sa
1
d
o
se
N
at
u
ra
ll
y-
in
fe
ct
ed
M
36
24
9/
27
1
(9
1.
9,
88
.0
–9
4.
8)
23
8/
27
8
(8
5.
6,
80
.9
–8
9.
5)
27
1/
51
0
(5
3.
1,
48
.7
–5
7.
5)
M
FI
18
4
(1
62
–2
08
)
M
FI
11
7
(1
04
–1
32
)
M
FI
45
(4
1–
49
)
–
Sa
n
ka
ra
n
ar
ay
an
an
20
18
[2
8]
M
36
27
1/
27
1
(1
00
.0
,9
8.
6–
10
0.
0)
27
8/
27
8
(1
00
.0
,9
8.
7–
10
0.
0)
51
0/
51
0
(1
00
.0
,
99
.3
–1
00
.0
)
M
FI
18
4
(1
62
–2
08
)
M
FI
11
7
(1
04
–1
32
)
M
FI
45
(4
1–
49
)
–
M
48
23
9/
23
9
(1
00
.0
,9
8.
5–
10
0.
0)
24
3/
24
3
(1
00
.0
,9
8.
5–
10
0.
0)
39
7/
39
7
(1
00
.0
,
99
.1
–1
00
.0
)
M
FI
13
3
(1
15
–1
54
)
M
FI
12
0
(1
05
–1
36
)
M
FI
47
(4
1–
53
)
–
C
I:
co
n
fi
de
n
ce
in
te
rv
al
;
H
PV
:
H
u
m
an
pa
pi
ll
om
av
ir
u
s;
M
M
on
th
;
R
R
:
R
is
k
ra
ti
o.
a
R
es
u
lt
s
ar
e
sh
ow
n
on
ly
fo
r
tw
o-
do
se
ar
m
s
w
h
er
e
pa
rt
ic
ip
an
ts
re
ce
iv
ed
do
se
on
e
at
da
y
0
an
d
do
se
da
y
at
da
y
18
0.
b
D
efi
n
it
io
n
s
of
se
ro
po
si
ti
vi
ty
u
se
d
in
ea
ch
st
u
dy
ar
e
pr
ov
id
ed
in
Su
pp
le
m
en
ta
ry
Ta
bl
e
5.
c
Se
ro
po
si
ti
vi
ty
pr
op
or
ti
on
s
(%
)
an
d
95
%
C
Is
w
er
e
ca
lc
u
la
te
d
by
th
e
au
th
or
s
of
th
is
re
vi
ew
u
si
n
g
da
ta
pr
ov
id
ed
in
th
e
in
cl
u
de
d
ar
ti
cl
es
.
d
H
PV
G
M
Ts
(9
5%
C
I)
am
on
g
11
3
u
n
va
cc
in
at
ed
bu
t
n
at
u
ra
ll
y
in
fe
ct
ed
co
n
tr
ol
s
w
er
e
15
(1
1–
19
)
fo
r
H
PV
16
an
d
15
(1
2–
19
)
fo
r
H
PV
18
[2
2]
.T
h
is
ar
ti
cl
e
di
d
n
ot
re
po
rt
ra
te
s
of
se
ro
po
si
ti
vi
ty
fo
r
M
6,
12
,2
4
or
36
fo
r
H
PV
16
,o
r
at
an
y
ti
m
e
po
in
t
fo
r
H
PV
18
.I
t
al
so
di
d
n
ot
re
po
rt
95
%
C
Is
fo
r
H
PV
16
/1
8
an
ti
bo
dy
ti
tr
es
pr
io
r
to
M
48
;
10
th
,2
5t
h
,7
5%
an
d
90
th
pe
rc
en
ti
le
s
w
er
e
re
po
rt
ed
in
th
e
ar
ti
cl
e
bu
t
n
ot
pr
es
en
te
d
in
th
is
re
vi
ew
.
e
M
on
th
48
re
su
lt
s
n
ot
sh
ow
n
as
re
po
rt
ed
on
ly
fo
r
tw
o-
an
d
th
re
e-
do
se
ar
m
s,
n
ot
fo
r
th
e
on
e-
do
se
ar
m
.
10 H.S. Whitworth et al. / Vaccine xxx (xxxx) xxx
Please cite this article as: H. S. Whitworth, K. E. Gallagher, N. Howard et al., Efficacy and immunogenicity of a single dose of human papillomavirus vaccine
compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials, Vaccine, https://doi.
org/10.1016/j.vaccine.2019.12.017
antibody levels required to provide protection against HPV infec-
tion is unknown [39].
This systematic review is limited by the small number of stud-
ies reporting clinical trial-based evaluations of single-dose HPV
vaccination, and in some studies, limited sample size of the one-
dose group. We identified only seven publications describing stud-
ies of single-dose HPV vaccination compared to either no vaccina-
tion or two- or three-dose schedules. Six were observational
studies arising from three randomised clinical trials (that were
investigating efficacy and immune responses in three doses versus
control, or two versus three doses), with participant allocation to
one-dose or comparator arms occurring retrospectively (due to
non-completion of originally-allocated schedules). Only one very
small pilot study allocated participants to one-dose versus no-
dose arms prospectively.
Furthermore, our review was not able to evaluate the effects of
gender, age or HIV status, as proposed in our study protocol, as all
studies conducted to date have been in young, healthy females.
This highlights a paucity of evidence in alternative target popula-
tions. Additionally, all trial-based data of single-dose HPV vaccina-
tion published to date come from Cervarix and Gardasil
recipients; no studies have evaluated Gardasil-9. Whilst 12
national programme-based studies included in the published
review by Markowitz et al. report on vaccine efficacy against
AGW and cervical abnormalities [17], the trial-based efficacy stud-
ies in our trials-based review reported only on HPV infection
endpoints.
Studying CVT, PATRICIA and IARC India HPV Vaccine Trial-
derived cohorts for evaluation of single- versus multi-dose vacci-
nation schedules minimises many of the biases that confound the
national programme-based studies, despite the retrospective allo-
cation to exposure versus comparator arms. However, retrospec-
tive allocation is still sub-optimal, so this approach does not
preclude the requirement for gold-standard purpose-designed,
prospectively-randomised, controlled trials. Also, although the
point estimates of vaccine effectiveness in the trial-based observa-
tional studies are high, the confidence intervals around the esti-
mates are very wide, which limits any strong conclusions from
these data on whether one dose is sufficient for protection.
It was not possible to combine results of the included studies
and perform a meta-analysis in this review due to considerable
heterogeneity between the studies (with respect to the vaccine
used, reasons for participants receiving a single dose, time points
evaluated, efficacy outcomes measured and laboratory assays
used). Thus, the data presented in our systematic review do not
benefit from the increased power and improved estimates of the
size of effect that are usually achieved through performing a
meta-analysis. Investigators conducting new and ongoing clinical
trials and observational studies aiming to evaluate single-dose
HPV vaccination are now working together to standardise meth-
ods, time points, endpoints and definitions [15,39]. This will allow
immunobridging between immunogenicity and efficacy trials, as
well as meta-analysis of data, which will be important for further
development of mathematical models for projecting long-term
sustainability of protection and immune responses.
5. Conclusions
Our systematic review of the literature on single-dose HPV vac-
cination from clinical trials supports the premise that one dose
may be as effective in preventing HPV infection as two or three
doses in healthy young females up to seven years post-
HPV16 HPV18
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Fig. 2. Magnitude of anti-HPV16 and 18 antibody responses (a) at 36 and 48 months post vaccination with 3, 2 or 1 dose of Gardasil in the IARC India HPV vaccine trial, and
(b) at 48 and 84 months post vaccination with 3, 2 or 1 dose of Cervarix in the CVT. Data shown are MFI with 95% CIs for Gardasil and GMT (EU/ml) with 95% CIs for Cervarix.
Corresponding seropositivity rates (and 95% CI) for each dosage group at the same time point are shown below the bars. Definitions of seropositivity in the two trials are
shown in Supplementary Table 5.
H.S. Whitworth et al. / Vaccine xxx (xxxx) xxx 11
Please cite this article as: H. S. Whitworth, K. E. Gallagher, N. Howard et al., Efficacy and immunogenicity of a single dose of human papillomavirus vaccine
compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials, Vaccine, https://doi.
org/10.1016/j.vaccine.2019.12.017
vaccination. Seropositivity rates were high among all HPV vaccine
recipients, also up to seven years post-vaccination. However, sus-
tained durability of the immune response will be fundamental to
longer-term protection, so further follow up of participants who
received different dosing schedules is important.
Whilst producing promising results, our systematic review also
highlights the existing paucity of available evidence appropriate
for informing policies and guidelines on HPV vaccination strate-
gies. Ongoing clinical trials [14,18] assessing the efficacy and
immunogenicity of single-dose HPV vaccination compared to
currently-recommended schedules will go a long way towards
addressing this knowledge gap for the target populations in those
trials. However, research on the efficacy of, and immune responses
to, single-dose HPV vaccination may need to be expanded to other
target groups such as boys, alternative age groups and HIV-positive
individuals, and should evaluate all licensed HPV vaccines, as well
as promising new vaccines currently in development.
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